<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="842">
  <stage>Registered</stage>
  <submitdate>18/10/2005</submitdate>
  <approvaldate>21/10/2005</approvaldate>
  <actrnumber>ACTRN12605000677606</actrnumber>
  <trial_identification>
    <studytitle>Cardioprotection for type II diabetic patients undergoing cardiopulmonary bypass: a comparison of 2 different anaesthetic agents.</studytitle>
    <scientifictitle>A randomised phase IV study to compare the effects of propofol and sevoflurane in preventing myocardial necrosis in non-insulin dependent diabetes mellitus patients undergoing coronary artery bypass graft surgery requiring cardiopulmonary bypass.</scientifictitle>
    <utrn />
    <trialacronym>N/A</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Postoperative myocardial damage</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular</conditioncode1>
      <conditioncode2 />
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A comparison of 2 different anaesthetic agents (propofol and sevoflurane) and their affect on cardioprotection in non insulin diabetic patients undergoing coronary artery bypass graft surgery requiring cardiopulmonary bypass.  2 groups of 20 patients each will be randomised to receive either propofol or sevoflurane to maintain general anaesthesia whilst on cardiopulmonary bypass.  Anaesthesia leading up to bypass will be the same in each group.  At 15 minutes post separation from bypass, both groups will receive sevoflurane anaesthesia alone.  Otherwise, management will be as per normal for coronary artery bypass patients.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>Prevention</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Blood measurement of the enzyme cardiac troponin i </outcome>
      <timepoint>At 12 and 24 hours post-admission to the intensive care unit after coronary artery bypass graft surgery.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Inotrope use and other haemodynamic support, haemodynamic data.</outcome>
      <timepoint>In the first 24 hours postoperatively.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Non insulin dependent diabetes mellitus patients, undergoing routine, primary coronary artery bypass graft surgery requiring cardiopulmonary bypass.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Those with a sensitivity to propofol or its components, acute or evolving myocardial infarction, peroperative haemodynamic instability, hepatorenal dysfunction, off pump or valvular surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>numbered, sealed envelopes. 20 for propofol and 20 for sevoflurane.</concealment>
    <sequence>coin toss to randomise the order of envelopes.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Other</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/01/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Dept of Anaesthesia</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>St Vincent's Hospital</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Diabetic patients will be randomised to receive one of two commonly used anaesthetic drugs to maintain general anaesthesia whilst on cardiopulmonary bypass.  We will be investigating which one  offers better cardioprotection as determined by measuring an enzyme called cardiac troponin i.  This enzyme is commonly measured to detect whther a myocardial infarction "heart attack" has occurred.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>St Vincent's Hospital</ethicname>
      <ethicaddress> Melbourne</ethicaddress>
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Bradley LA FERLITA</name>
      <address>c/- Department of Anaesthesia
St Vincent's Hospital
Victoria Pde
Fitzroy VIC 3065</address>
      <phone>+61 3 92882211</phone>
      <fax>+61 3 92884255</fax>
      <email>bradley.laferlita@svhm.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Bradley LA FERLITA</name>
      <address>c/- Department of Anaesthesia
St Vincent's Hospital
Victoria Pde
Fitzroy VIC 3065</address>
      <phone>+61 3 92882211</phone>
      <fax>+61 3 92884255</fax>
      <email>bradley.laferlita@svhm.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>